Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Protagonist Therapeutics stock | $35.11
Learn how to easily invest in Protagonist Therapeutics stock.
Protagonist Therapeutics, Inc is a biotechnology business based in the US. Protagonist Therapeutics shares (PTGX) are listed on the NASDAQ and all prices are listed in US Dollars. Protagonist Therapeutics employs 83 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Protagonist Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – PTGX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Protagonist Therapeutics stock price (NASDAQ: PTGX)Use our graph to track the performance of PTGX stocks over time.
Protagonist Therapeutics shares at a glance
|Latest market close||$35.11|
|52-week range||$14.16 - $49.50|
|50-day moving average||$44.44|
|200-day moving average||$32.01|
|Wall St. target price||$44.14|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.74|
Buy Protagonist Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Protagonist Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Protagonist Therapeutics price performance over time
|1 week (2021-07-24)||N/A|
|1 month (2021-07-02)||-24.27%|
|3 months (2021-05-04)||19.63%|
|6 months (2021-01-31)||N/A|
|1 year (2020-07-31)||N/A|
|2 years (2019-07-31)||N/A|
|3 years (2018-07-31)||N/A|
|5 years (2016-07-31)||N/A|
Protagonist Therapeutics financials
|Revenue TTM||$31.2 million|
|Gross profit TTM||$28.6 million|
|Return on assets TTM||-19.87%|
|Return on equity TTM||-43.52%|
|Market capitalisation||$2.3 billion|
TTM: trailing 12 months
Shorting Protagonist Therapeutics shares
There are currently 3.4 million Protagonist Therapeutics shares held short by investors – that's known as Protagonist Therapeutics's "short interest". This figure is 1.7% down from 3.5 million last month.
There are a few different ways that this level of interest in shorting Protagonist Therapeutics shares can be evaluated.
Protagonist Therapeutics's "short interest ratio" (SIR)
Protagonist Therapeutics's "short interest ratio" (SIR) is the quantity of Protagonist Therapeutics shares currently shorted divided by the average quantity of Protagonist Therapeutics shares traded daily (recently around 553269.69205835). Protagonist Therapeutics's SIR currently stands at 6.17. In other words for every 100,000 Protagonist Therapeutics shares traded daily on the market, roughly 6170 shares are currently held short.
However Protagonist Therapeutics's short interest can also be evaluated against the total number of Protagonist Therapeutics shares, or, against the total number of tradable Protagonist Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Protagonist Therapeutics's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Protagonist Therapeutics shares in existence, roughly 70 shares are currently held short) or 0.1162% of the tradable shares (for every 100,000 tradable Protagonist Therapeutics shares, roughly 116 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Protagonist Therapeutics.
Find out more about how you can short Protagonist Therapeutics stock.
Protagonist Therapeutics share dividends
We're not expecting Protagonist Therapeutics to pay a dividend over the next 12 months.
Protagonist Therapeutics share price volatility
Over the last 12 months, Protagonist Therapeutics's shares have ranged in value from as little as $14.16 up to $49.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Protagonist Therapeutics's is 1.5606. This would suggest that Protagonist Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Protagonist Therapeutics overview
Protagonist Therapeutics, Inc. , a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. It is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PTG-200, an oral, interleukin-23 receptor specific antagonist peptide, which is in phase II clinical trial for the treatment of moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase II clinical trial for treating inflammatory bowel disease (IBD). The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn's disease and ulcerative colitis; and PN-235 and PN-232 oral interleukin-23 receptor antagonist candidates for IBD and non-IBD indications. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Stocks similar to Protagonist Therapeutics
Protagonist Therapeutics in the news
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
Stocks That Hit 52-Week Highs On Friday
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
Frequently asked questionsWhat percentage of Protagonist Therapeutics is owned by insiders or institutions?
Currently 1.46% of Protagonist Therapeutics shares are held by insiders and 99.127% by institutions. How many people work for Protagonist Therapeutics?
Latest data suggests 83 work at Protagonist Therapeutics. When does the fiscal year end for Protagonist Therapeutics?
Protagonist Therapeutics's fiscal year ends in December. Where is Protagonist Therapeutics based?
Protagonist Therapeutics's address is: 7707 Gateway Boulevard, Newark, CA, United States, 94560-1160 What is Protagonist Therapeutics's ISIN number?
Protagonist Therapeutics's international securities identification number is: US74366E1029 What is Protagonist Therapeutics's CUSIP number?
Protagonist Therapeutics's Committee on Uniform Securities Identification Procedures number is: 74366E102
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert